Radiofrequency ablation beyond the liver.
Radiofrequency ablation (RFA) has begun to show promise for extrahepatic indications. Although much of the reported work on image-guided RFA of liver neoplasms is quite promising, it is even earlier in the evaluation and validation process for extrahepatic RFA, with few short-term and no long-term studies reported. Although there are much more data for liver RFA with almost 3,000 cases reported in the literature, there are a number of ongoing investigations of RFA for tumors in the kidney, lung, bone, breast, bone, and adrenal gland. Debulking and pain control with RFA present palliative options becoming increasingly popular weapons in the interventionalist's oncology arsenal. Metastatic disease with a wide variety of primary histologies in a myriad of locations may be treated with RFA after a careful consideration of the risk-to-benefit ratio balance. The RFA technique can be slightly different outside the liver. Specifically, differing dielectric tissue characteristics may markedly alter the RFA treatment. Each different RFA system has a unique risk and advantage profile. Extrahepatic indications and contraindications will be suggested. Treatment tips and the unique complications and considerations will be introduced for some of the more common extrahepatic locations.
Neeman
Ziv
Z
Diagnostic Radiology Department, National Institutes of Health Clinical Center and National Cancer Institute, Bethesda, MD 20892, USA.
Wood
Bradford J
BJ
D000310:Adrenal Gland Neoplasms / Q000601:surgery; D001859:Bone Neoplasms / Q000601:surgery; D001943:Breast Neoplasms / Q000601:surgery; D017115:Catheter Ablation / Q000295:instrumentation; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000601:surgery*; D010146:Pain / Q000601:surgery; D010166:Palliative Care; D011859:Radiography